BridgeBio's Breakthrough: Oral Drug Succeeds in Dwarfism Study
BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.
NOTRELOAD AI
Fermi America Teams Up with Hyundai to Restart Big Nuclear Power in the US
Fermi America is partnering with Hyundai E&C to build massive nuclear plants for Project Matador in Texas. This could power AI data centers and restart large-scale US nuclear construction.
Seres Therapeutics Shifts Focus to Promising New Programs
Seres Therapeutics announces pauses in some studies, workforce cuts, and a new emphasis on treatments for inflammatory and immune diseases like ulcerative colitis, aiming to extend cash through 2026.
Raymond James Upgrades Oscar Health to Outperform – Sees Big Upside
Raymond James upgrades Oscar Health stock to Outperform with $18 target, calling valuations attractive as margins improve in ACA market and forward outlook strengthens.
Quantum Computing Stocks: Analyst Shifts Views on Rigetti and D-Wave
TD Cowen analyst updates ratings on Rigetti Computing and initiates coverage on D-Wave Quantum – one faces valuation and competition risks, while the other gets a positive nod for its tech edge.
FDA Approves Novocure's Optune Pax: A New Hope for Pancreatic Cancer Patients
Novocure's Optune Pax wearable device wins FDA approval for locally advanced pancreatic cancer with gemcitabine + nab-paclitaxel. Phase 3 trial shows improved survival and delayed pain progression.